Dr Chigo Munthali MD, MFPM

Consultant Pharmaceutical Physician l Medical Director

Dr Chigo Munthali is a Consultant Pharmaceutical Physician and Medical Director with extensive experience in clinical medicine, pharmaceutical development, and medical leadership. As a Member of the Faculty of Pharmaceutical Medicine (MFPM), she brings a wealth of expertise in evidence-based healthcare and clinical governance.

At Repose Healthcare, Dr Munthali provides strategic medical leadership, ensuring that the company’s services are underpinned by sound clinical principles, robust governance, and a client-centred approach. She works closely with the scientific and operational teams to help ensure that our diagnostic services meet the highest standards of quality, safety, and clinical relevance.

Throughout his career, Dr Munthali has been committed to advancing healthcare through innovation, scientific excellence, and the application of best clinical practice. Her experience spans medical affairs, regulatory medicine, and the development of healthcare solutions that improve patient outcomes while maintaining the highest ethical and professional standards.

Passionate about expanding access to high-quality healthcare, Dr Munthali is dedicated to supporting Repose Healthcare’s mission of making trusted diagnostic testing more accessible. Her leadership and medical expertise help ensure that our services continue to deliver meaningful, reliable, and patient-focused healthcare solutions.

Publications

  1. Munthali C et al. Diagnostic accuracy of the WHO clinical staging system fordefining eligibility for antiretroviral therapy in sub-Saharan Africa: a systematic review and meta-analysis. Journal of the International AIDS Society2014,17:18932
  2. MacPherson P, Munthali C, Ferguson J, Armstrong A, Kranzer K, Ferrand RA, Ross DA. Service delivery interventions to improve adolescents' linkage, retention and adherence to antiretroviral therapy and HIV care. Trop Med Int Health. 2015 Aug;20(8):1015-32
  3. Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, Chadwick DR, Clark R, Cosgrove CA, Galloway J, Goodman AL, Heer A, Higham A, Iyengar S, Jeanes C, Kalra PA, Kyriakidou C, Bradley JM, Munthali C, Minassian AM, McGill F, Moore P, Munsoor I, Nicholls H, Osanlou O, Packham J, Pretswell CH, Francisco Ramos AS, Saralaya D, Sheridan RP, Smith R, Soiza RL, Swift PA, Thomson EC, Turner J, Viljoen ME, Fries L, Cho I, McKnight I, Glenn G, Rivers EJ, Robertson A, Alves K, Smith K, Toback S. Safety and Efficacy of the NVX-CoV2373 COVID-19 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial. Clin Infect Dis. 2022 Oct 10:ciac803
  4. Taylor Cohen, Marimer Rensoli Valzquez, Chigo Munthali, Herve Tchouakam Kouekam, Sam Matthews, Audrey Sharbaugh, Rohini Beavon, Dilki Wickramarachchi, Sharon Otal, Haitao Yang, Anastasia A Aksyuk, Lindsay E Clegg, Huixia Zhang, Antonella Nadia Tuillio, Seth Seegobin, Katie Streicher, David Wheeler, Lee-Jah Chang, Hugh Montgomery, P-1969. Safety, Immunogenicity, and Pharmacokinetics of Repeat Dosing with AZD7442 (Tixagevimab/Cilgavimab): Final Analysis of the ENDURE Phase 2, Dose-Ranging Study in Immunocompromised Participants, Open Forum Infectious Diseases, Volume 12, Issue Supplement_1, February 2025, ofae631.2128, https://doi.org/10.1093/ofid/ofae631.2128